Industry: Pharmaceuticals, Biotechnology
DaoGen, Inc. is a privately held biotechnology company dedicated to the discovery and development of novel cancer therapeutics. DaoGen’s lead product candidates, monoclonal antibodies directed against Wnt-1 and Wnt-2, have already demonstrated potent anti-tumor activities in a wide variety of pre-clinical cancer studies. The Company has licensed several oncology targets and other technology from the University of California, San Francisco (UCSF). Each of these targets and the anti-Wnt product candidates were identified by its founder, Dr. David Jablons, Director of the Thoracic Oncology Program and Chief of the Section of General Thoracic Surgery, and his team at the Thoracic Oncology Laboratory in the UCSF Comprehensive Cancer ( www.daogen.com )
DaoGen Inc
863A Mitten Road
Burlingame, California 94010
USA
Tel: (888) 650-9818
Fax: (650) 240-0420